Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 1,314,619 |
|
|||||
| News | - | ||||||
| Day High | 1.79 | Low High |
|||||
| Day Low | 1.6301 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| BioVie Inc | BIVI | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.11 | -6.11% | 1.69 | 00:00:09 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.74 | 1.6301 | 1.79 | 1.68 | 1.80 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5,951 | 1,314,619 | $ 1.70 | $ 2,234,182 | - | 1.50 - 14.38 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:56:45 | 50 | $ 1.75 | USD |
BioVie Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 64.54M | 37.74M | - | 0 | -50.26M | -1.33 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
BioVie News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BIVI Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.99 | 5.654 | 1.50 | 2.41 | 2,700,390 | -3.30 | -66.13% |
| 1 Month | 4.45 | 5.82 | 1.50 | 3.08 | 1,245,181 | -2.76 | -62.02% |
| 3 Months | 3.27 | 5.82 | 1.50 | 3.29 | 685,554 | -1.58 | -48.32% |
| 6 Months | 5.94 | 6.45 | 1.50 | 3.67 | 440,345 | -4.25 | -71.55% |
| 1 Year | 6.75 | 14.38 | 1.50 | 6.25 | 591,735 | -5.06 | -74.96% |
| 3 Years | 9.80 | 46.0977 | 1.325 | 6.76 | 279,937 | -8.11 | -82.76% |
| 5 Years | 10.50 | 46.0977 | 1.325 | 6.78 | 264,507 | -8.81 | -83.9% |
BioVie Description
| BioVie Inc is a company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is currently focused on developing and commercializing BIV201, a novel investigational approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism. |
